<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               6. ADVERSE REACTIONS <BR>               <BR>                  Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<BR>                  In Studies A and B, patients with locally advanced or metastatic ALK-positive NSCLC received crizotinib 250 mg orally twice daily continuously. Among the 255 patients for whom data on Grade 1–4 adverse reactions are available, median exposure to study drug was 5.1 months in Study A and 7.8 months in Study B. Dosing interruptions occurred in 36% and 45% of patients in Studies A and B, and lasted greater than 2 weeks in 13% and 19% of patients in Studies A and B, respectively. Dose reductions occurred in 44% and 29% of patients in Studies A and B, respectively. The rates of treatment-related adverse events resulting in permanent discontinuation were 6% in Study A and 3% in Study B. The most common adverse reactions (≥25%) across both studies were vision disorder, nausea, diarrhea, vomiting, edema, and constipation. Grade 3–4 adverse reactions in at least 4% of patients in both studies included ALT increased and neutropenia. <BR>                  Among the 397 patients for whom information on deaths and serious adverse reactions is available, deaths within 28 days of the last dose of study drug occurred in 45 patients. Ten (2.5%) patients died within 28 days of their first dose of study drug. Causes of death included disease progression (32 patients), respiratory events (9), and other (4). Respiratory causes of death included pneumonia (2), hypoxia (2), ARDS (1), dyspnea (1), pneumonitis (1), empyema (1), and pulmonary hemorrhage (1). Other causes of deaths included septic shock, DIC, cardiovascular event, and death due to unknown cause (1 each). Serious adverse events in greater than or equal to 2% of patients included pneumonia, dyspnea, and pulmonary embolism. <BR>                  <BR>                     Table 3 lists the common adverse reactions on Studies A and B in patients receiving XALKORI.<BR>                  <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" width="100%" ID="t3"><BR>                     <caption>Table 3: Adverse Reactions in &#8805;10% of Patients with Locally Advanced or Metastatic ALK-Positive NSCLC on Studies A and B<footnote ID="table3a">Study A used CTCAE v4.0, and Study B used CTCAE v3.0.</footnote><BR>                     </caption><BR>                     <col width="35%" align="left" valign="top"/><BR>                     <col width="15%" align="center" valign="top"/><BR>                     <col width="15%" align="center" valign="top"/><BR>                     <col width="15%" align="center" valign="top"/><BR>                     <col width="20%" align="center" valign="top"/><BR>                     <thead><BR>                        <tr styleCode="Botrule"><BR>                           <th styleCode="Lrule Rrule">Adverse Event</th><BR>                           <th styleCode="Rrule" colspan="2">Treatment Emergent<br/>N=255</th><BR>                           <th styleCode="Rrule" colspan="2">Treatment Related<br/>N=255</th><BR>                        </tr><BR>                        <tr><BR>                           <th styleCode="Lrule Rrule"/><BR>                           <th styleCode="Rrule">All Grades<br/>n (%)</th><BR>                           <th styleCode="Rrule">Grade 3/4<br/>n (%)</th><BR>                           <th styleCode="Rrule">All Grades<br/>n (%)</th><BR>                           <th styleCode="Rrule">Grade 3/4<br/>n (%)</th><BR>                        </tr><BR>                     </thead><BR>                     <tbody><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Eye Disorders</content><BR>                           </td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Vision Disorder<footnote ID="table3b">Includes diplopia, photopsia, photophobia, vision blurred, visual field defect, visual impairment, vitreous floaters, visual brightness, and visual acuity reduced.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">163 (64%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                           <td styleCode="Rrule">159 (62%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Gastrointestinal Disorders</content><BR>                           </td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Nausea</td><BR>                           <td styleCode="Rrule">145 (57%)</td><BR>                           <td styleCode="Rrule">2 (&lt;1%)</td><BR>                           <td styleCode="Rrule">136 (53%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Diarrhea</td><BR>                           <td styleCode="Rrule">124 (49%)</td><BR>                           <td styleCode="Rrule">1 (&lt;1%)</td><BR>                           <td styleCode="Rrule">109 (43%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Vomiting</td><BR>                           <td styleCode="Rrule">116 (45%)</td><BR>                           <td styleCode="Rrule">3 (1%)</td><BR>                           <td styleCode="Rrule">101 (40%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Constipation</td><BR>                           <td styleCode="Rrule">98 (38%)</td><BR>                           <td styleCode="Rrule">2 (&lt;1%)</td><BR>                           <td styleCode="Rrule">69 (27%)</td><BR>                           <td styleCode="Rrule">1 (&lt;1%)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Esophageal Disorder<footnote ID="table3c">Includes dyspepsia, dysphagia, epigastric discomfort/pain/burning, esophagitis, esophageal obstruction/pain/spasm/ulcer, 	gastroesophageal reflux, odynophagia, and reflux esophagitis.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">51 (20%)</td><BR>                           <td styleCode="Rrule">3 (1%)</td><BR>                           <td styleCode="Rrule">29 (11%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Abdominal Pain<footnote ID="table3d">Includes abdominal discomfort, abdominal pain, abdominal pain upper, and abdominal tenderness.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">40 (16%)</td><BR>                           <td styleCode="Rrule">1 (&lt;1%)</td><BR>                           <td styleCode="Rrule">20 (8%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Stomatitis<footnote ID="table3e">Includes mouth ulceration, glossodynia, glossitis, cheilitis, mucosal inflammation, oropharyngeal pain/discomfort, oral pain, and stomatitis.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">27 (11%)</td><BR>                           <td styleCode="Rrule">1 (&lt;1%)</td><BR>                           <td styleCode="Rrule">15 (6%)</td><BR>                           <td styleCode="Rrule">1 (&lt;1%)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">General Disorders</content><BR>                           </td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Edema<footnote ID="table3f">Includes edema, edema localized, and peripheral edema.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">97 (38%)</td><BR>                           <td styleCode="Rrule">2 (&lt;1%)</td><BR>                           <td styleCode="Rrule">72 (28%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Fatigue</td><BR>                           <td styleCode="Rrule">80 (31%)</td><BR>                           <td styleCode="Rrule">6 (2%)</td><BR>                           <td styleCode="Rrule">51 (20%)</td><BR>                           <td styleCode="Rrule">4 (2%)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Chest Pain/Discomfort<footnote ID="table3g">Includes chest pain, chest discomfort, and musculoskeletal chest pain.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">30 (12%)</td><BR>                           <td styleCode="Rrule">1 (&lt;1%)</td><BR>                           <td styleCode="Rrule">3 (1%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Fever</td><BR>                           <td styleCode="Rrule">30 (12%)</td><BR>                           <td styleCode="Rrule">1 (&lt;1%)</td><BR>                           <td styleCode="Rrule">2 (&lt;1%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Infections and Infestations</content><BR>                           </td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Upper Respiratory Infection<footnote ID="table3h">Includes nasopharyngitis, rhinitis, pharyngitis, and upper respiratory tract infection.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">50 (20%)</td><BR>                           <td styleCode="Rrule">1 (&lt;1%)</td><BR>                           <td styleCode="Rrule">4 (2%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Investigations</content><BR>                           </td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Alanine Aminotransferase Increased</td><BR>                           <td styleCode="Rrule">38 (15%)</td><BR>                           <td styleCode="Rrule">17 (7%)</td><BR>                           <td styleCode="Rrule">34 (13%)</td><BR>                           <td styleCode="Rrule">14 (5%)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Aspartate Aminotransferase Increased</td><BR>                           <td styleCode="Rrule">29 (11%)</td><BR>                           <td styleCode="Rrule">7 (3%)</td><BR>                           <td styleCode="Rrule">24 (9%)</td><BR>                           <td styleCode="Rrule">5 (2%)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Metabolism and Nutrition</content><BR>                           </td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Decreased Appetite</td><BR>                           <td styleCode="Rrule">69 (27%)</td><BR>                           <td styleCode="Rrule">3 (1%)</td><BR>                           <td styleCode="Rrule">49 (19%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Musculoskeletal</content><BR>                           </td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Arthralgia</td><BR>                           <td styleCode="Rrule">29 (11%)</td><BR>                           <td styleCode="Rrule">3 (1%)</td><BR>                           <td styleCode="Rrule">4 (2%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Back Pain</td><BR>                           <td styleCode="Rrule">28 (11%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                           <td styleCode="Rrule">2 (&lt;1%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Nervous System Disorders</content><BR>                           </td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Dizziness<footnote ID="table3i">Includes balance disorder, dizziness, and presyncope.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">60 (24%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                           <td styleCode="Rrule">42 (16%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Neuropathy<footnote ID="tablej">Includes burning sensation, dysesthesia, hyperesthesia, hypoesthesia, neuralgia, paresthesia, peripheral neuropathy, 	peripheral motor neuropathy, and peripheral sensory neuropathy.</footnote><BR>                           </td><BR>                           <td styleCode="Rrule">58 (23%)</td><BR>                           <td styleCode="Rrule">1 (&lt;1%)</td><BR>                           <td styleCode="Rrule">34 (13%)</td><BR>                           <td styleCode="Rrule">1 (&lt;1%)</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Headache </td><BR>                           <td styleCode="Rrule">34 (13%)</td><BR>                           <td styleCode="Rrule">1 (&lt;1%)</td><BR>                           <td styleCode="Rrule">10 (4%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Dysgeusia</td><BR>                           <td styleCode="Rrule">33 (13%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                           <td styleCode="Rrule">30 (12%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Psychiatric Disorders</content><BR>                           </td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Insomnia</td><BR>                           <td styleCode="Rrule">30 (12%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                           <td styleCode="Rrule">8 (3%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Respiratory Disorders</content><BR>                           </td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Dyspnea</td><BR>                           <td styleCode="Rrule">57 (22%)</td><BR>                           <td styleCode="Rrule">16 (6%)</td><BR>                           <td styleCode="Rrule">5 (2%)</td><BR>                           <td styleCode="Rrule">3 (1%)</td><BR>                        </tr><BR>                        <tr styleCode="Botrule"><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Cough</td><BR>                           <td styleCode="Rrule">54 (21%)</td><BR>                           <td styleCode="Rrule">3 (1%)</td><BR>                           <td styleCode="Rrule">9 (4%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule"><BR>                              <content styleCode="bold">Skin Disorders</content><BR>                           </td><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                           <td styleCode="Rrule"/><BR>                        </tr><BR>                        <tr><BR>                           <td styleCode="Lrule Rrule">&#160;&#160;Rash</td><BR>                           <td styleCode="Rrule">41 (16%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                           <td styleCode="Rrule">25 (10%)</td><BR>                           <td styleCode="Rrule">0</td><BR>                        </tr><BR>                     </tbody><BR>                  </table><BR>                  <BR><BR><BR>Vision disorders including visual impairment, photopsia, vision blurred, vitreous floaters, photophobia, and diplopia were reported in 159 (62%) patients in clinical trials. These events generally started within two weeks of drug administration. Consider ophthalmological evaluation, particularly if patients experience photopsia or experience new or increased vitreous floaters. Severe or worsening vitreous floaters and/or photopsia could also be signs of a retinal hole or pending retinal detachment. Advise patients to exercise caution when driving or operating machinery due to the risk of developing a vision disorder [see Patient Counseling Information (17)].<BR>                  <BR>                  Neuropathy as defined in Table 3 and attributed to study drug by the investigator was reported in 34 (13%) patients. While most events were Grade 1, Grade 2 motor neuropathy and Grade 3 peripheral neuropathy were reported in 1 patient each. Dizziness and dysgeusia were also very commonly reported in these studies, but were all Grade 1 or 2 in severity.<BR>                  Bradycardia occurred in 12 (5%) patients treated with XALKORI. All of these cases were Grade 1 or 2 in severity.<BR>                  Complex renal cysts occurred in 2 (1%) patients treated with XALKORI. There were no reports of abnormal urinalyses or renal impairment in these cases.<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        The most common adverse reactions (≥25%) are vision disorder, nausea, diarrhea, vomiting, edema, and constipation. (6)<BR>                        <BR><BR>                        <BR>                           To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     <BR>                        <BR>                           Laboratory Abnormalities<BR>                        <BR>                        Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred in 5.2%, 0.4%, and 11.4% of patients, respectively.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>